Relationships between the presence /absence of various gene mutations and the efficacy of molecular targeted agents have been identified in various cancers; for example, the efficacy of anti-EGFR antibody was limited to colorectal cancer patients with wild-type KRAS expression in the tumor [31]. The gene discussed is KRAS; the disease is neoplasm.